Also known as: Ac-Epitalon, Acetylated Epithalon, N-Acetyl Epithalon Amidate
Half-life: Extended vs. parent Epitalon (acetylation effect)
Last reviewed: · Published:
N-Acetyl Epitalon is a chemically modified version of the well-known Russian longevity peptide Epitalon (Epithalon, Ala-Glu-Asp-Gly), with an N-terminal acetyl group added to protect the molecule from N-terminal aminopeptidase degradation. The acetylation generally increases peptide stability in plasma and tissues, extends circulating half-life, and may improve oral or sublingual bioavailability. The pharmacological activity is presumed to be equivalent to (and potentially more durable than) native Epitalon: telomerase activation, lengthening of telomeres in dividing cells, modulation of pineal melatonin production, and various reported anti-aging effects in long-running Russian studies by Vladimir Khavinson and colleagues.
The published literature on N-Acetyl Epitalon specifically is much thinner than for the parent compound. Almost all peer-reviewed publications use unmodified Epitalon; the acetylated variant has emerged in the research-chemical market with the rationale that the modification improves practical pharmacokinetics without changing the underlying biology. This is a reasonable extrapolation but not directly proven for the N-acetyl version.
Users should treat N-Acetyl Epitalon as functionally equivalent to Epitalon for practical purposes, while keeping in mind that the underlying clinical evidence base — even for the parent compound — consists primarily of long-running Russian observational and small interventional studies that have not been independently replicated in Western settings.
Epitalon was developed in the 1980s-90s by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, as a synthetic short-peptide derivative of bovine pineal gland extract (Epithalamin). The N-acetylated variant emerged in the 2010s as part of the broader trend toward chemically modified analogs of established Russian peptides, designed to offer practical pharmacokinetic advantages while preserving the bioactivity of the parent compound. It has not been independently characterized in published peer-reviewed studies to the degree the parent Epitalon has.
Russian clinical and observational studies of native Epitalon over multiple decades have reported excellent tolerability with no major adverse events. N-Acetyl Epitalon specifically has limited independent safety data but is presumed similar. The principal theoretical concern with any telomerase-activating compound is the possibility of accelerating proliferation of pre-existing dysplastic or neoplastic cells — though this has not been demonstrated as a clinical problem in the Khavinson-group studies, the absence of formal Western oncology safety studies leaves the question unsettled.
Dose Range
5-10 mg
Frequency
Once daily
Duration
10-20 day cycles, repeated 2-3 times per year
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
5 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2 mL
Half-Life
Extended vs. parent Epitalon (acetylation effect)
Molecular Weight
~432 Da
Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days (acetylation provides additional stability). Subcutaneous or intranasal administration; the acetyl modification may improve sublingual bioavailability.
FDA Status
Not FDA approved.
Legal Status
Unregulated research chemical.
USA
Not approvedResearch-only
EU
Not approvedNot authorized as medicinal product
UK
Not approvedClassified as research chemical
Russia
Not approvedParent Epitalon used in clinical/observational research; N-acetyl variant not separately registered
Australia
Not approvedTGA has not evaluated
Canada
Not approvedNot authorized for human use
Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS
Bulletin of Experimental Biology and Medicine (2015)
Comprehensive review by the Khavinson group summarizing 35 years of research on short-peptide bioregulators including Epitalon, providing the foundational scientific context applicable to both the parent and N-acetylated variant.
View Study →Khavinson VK, Bondarev IE, Butyugov AA
Bulletin of Experimental Biology and Medicine (2003)
Animal lifespan extension studies of Epitalon in fruit flies and mice — the model-organism evidence base most often cited in support of human anti-aging claims about Epitalon and its acetylated derivatives.
View Study →Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA
Bulletin of Experimental Biology and Medicine (2020)
Modern Khavinson-group review of proposed molecular mechanisms by which short bioregulator peptides including Epitalon affect gene expression — relevant to understanding the biological rationale for N-acetylated variants.
View Study →Synthetic pineal tetrapeptide that activates telomerase and modulates melatonin production.
Neuroprotective tripeptide bioregulator that penetrates the nuclear membrane to directly regulate gene expression in brain tissue.
D-retro-inverso senolytic peptide — selectively kills senescent cells via FOXO4-p53 disruption.
Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis.
Track N-Acetyl Epitalon and more with PinnyPeptide.
Sign Up to Track N-Acetyl EpitalonFree forever · defaults pre-filled from this article